NWBO — NORTHWEST BIOTHERAPEUTICS INC

OTC · Health Care · Pharmaceuticals · CIK 1072379 ·
Last close
$0.21
Market Cap
$343.46M
52W High
$0.30
52W Low
$0.19
ADV30
4,023,026
Next earnings
2026-08-13
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 494,000 -10,900,000 -3,069,000 80,051,000 1,786,000 130,595,000
Dec 2025 672,000 -13,504,000 1,388,000 81,290,000 3,040,000 141,570,000
Sep 2025 200,000 -14,320,000 -26,829,000 30,609,000 4,560,000 139,257,000
Jun 2025 131,000 -14,779,000 -15,378,000 29,547,000 4,316,000 129,936,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-44,763,000
Investing CF
$-1,815,000
Financing CF
$49,327,000
CapEx
$-1,504,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.06
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,503,661,000
Inventory
Receivables
$311,000
ST Investments
EBIT TTM
$-52,004,000
Pretax Income TTM
$-60,699,000
Interest Exp TTM
$8,695,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,497,000
EBITDA
$-51,102,000
Free Cash Flow
$-36,918,752
Enterprise Value
$418,150,848
Total Cash
$1,786,000
Total Debt
$63,994,000
Shares Out
1,643,343,757
Trailing EPS
$-0.03
Book Value
$-0.04
ROE
ROA
-62.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 1,378,000 -59,914,000 -60,162,000 81,290,000 141,570,000 -44,763,000
Dec 2024 1,382,000 -66,508,000 -83,778,000 26,728,000 121,215,000 -57,017,000
Dec 2023 1,932,000 -55,508,000 -62,599,000 27,865,000 93,638,000 -53,637,000
Dec 2022 1,683,000 -67,181,000 -105,032,000 31,323,000 159,426,000 -52,775,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.07

Peers — same industry

TickerNameMarket CapLastDaily %
ORGO Organogenesis Holdings Inc. $342.27M $2.66
IMRX Immuneering Corp $340.96M $5.27
DMAC DiaMedica Therapeutics Inc. $340.54M $6.32
SIGA SIGA TECHNOLOGIES INC $334.95M $4.67
IRD Opus Genetics, Inc. $332.91M $4.09

News headlines (Yahoo Finance, 1h cache)

Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
2026-04-30 16:30 · Yahoo
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
2026-04-21 13:30 · Yahoo
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
2025-11-20 19:40 · Yahoo
Northwest Biotherapeutics: Q3 Earnings Snapshot
2025-11-14 22:47 · Yahoo
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
2025-10-24 16:03 · Yahoo
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
2025-08-27 16:39 · Yahoo
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
2025-08-18 16:37 · Yahoo
Northwest Biotherapeutics: Q2 Earnings Snapshot
2025-08-14 22:04 · Yahoo
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
2025-06-11 16:49 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.